New hope for young brain tumor patients: experimental drug combo enters trials
NCT ID NCT07389278
First seen Feb 05, 2026 · Last updated Apr 29, 2026 · Updated 11 times
Summary
This study tests whether adding an experimental drug (ADI-PEG 20) to standard radiation and chemotherapy can help children, teens, and young adults with a newly diagnosed aggressive brain tumor called high-grade glioma. About 97 participants will receive the drug combination to see if it is safe and delays tumor growth. The goal is to improve outcomes for these hard-to-treat tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.